Dr. Shah at UCSF is enrolling patients for a stop dasatinib study. If you are interested, please contact study coordinator Anna Arauz at ArauzA@cc.ucsf.edu. Some parameters for the study: "They must have been treated with dasatinib for at least two years, and in a dasatinib-induced complete molecular response for at least nine months. They cannot have had more than one prior TKI, and cannot have been treated with prior stem cell transplantation. Additionally, they cannot have ever had accelerated or blast phase CML."
I'm just helping to spread the word! Feel free to forward as appropriate.
Thanks!
